nach oben

Erschienen in:

11.09.2023 | Niere und Herz | CME

Kardiovaskuläre Therapie bei chronischer Nierenerkrankung

verfasst von: Prof. Dr. Dr. med. Vincent Brandenburg, PD Dr. med. Turgay Saritas, Prof. Dr. Dr. med. Stephan H. Schirmer, PD Dr. med. Kyrill Rogacev, Prof. Dr. med. Gunnar Henrik Heine

Erschienen in: Herz | Ausgabe 5/2023

zum CME-Kurs Einloggen, um Zugang zu erhalten

Zusammenfassung

Patienten mit kombinierten Herz- und Nierenerkrankungen stellen im klinischen Alltag eine besondere Herausforderung dar, denn sie weisen ein besonderes Risikoprofil für erhöhte Morbidität und Mortalität auf. Gleichzeitig sind sie in evidenzliefernden Behandlungsstudien oft unterrepräsentiert, was dazu führt, dass kardiologische Therapieleitlinien in dieser Gruppe oft nicht den gleichen Empfehlungsgrad wie bei nierengesunden Patienten mit Herz-Kreislauf-Erkrankungen haben. Hinzu kommen Limitationen bei der Medikamentenzulassung in Abhängigkeit von der Nierenfunktion. Die Autoren greifen im Folgenden alltagsrelevante Bereiche für Patienten mit kardiovaskulären Erkrankungen auf, deren Behandlung von einer zusätzlichen chronischen Nierenerkrankung maßgeblich beeinflusst wird.

Damman K, Valente MA, Voors AA et al (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35(7):455–469CrossRefPubMed

Gansevoort RT, Anders HJ, Cozzolino M et al (2023) What should European nephrology do with the new CKD-EPI equation? Nephrol Dial Transplant 38(1):1–6CrossRefPubMed

Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158(11):825–830CrossRefPubMed

KDIGO („Kidney Disease: Improving Global Outcomes“) https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf. Zugegriffen: September 2023

Visseren FLJ, Mach F, Smulders YM, Carballo D et al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42(34):3227–3337CrossRefPubMed

Mach F, Baigent C, Catapano AL et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41(1):111–188CrossRefPubMed

Wanner C, Krane V, März W et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238–248CrossRefPubMed

Drechsler C, Grootendorst DC, Pilz S et al (2011) Wasting and sudden cardiac death in hemodialysis patients: a post hoc analysis of 4D (Die Deutsche Diabetes Dialyse Studie). Am J Kidney Dis 58(4):599–607CrossRefPubMed

Fellström BC, Jardine AG, Schmieder RE et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360(14):1395–1407CrossRefPubMed

10.

Baigent C, Landray MJ, Reith C et al (2011) The effects of lowering LDL cholesterol with bsimvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet 377(9784):2181–2192CrossRefPubMedPubMedCentral

11.

Tonelli M, Wanner C (2014) Lipid management in chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 160(3):182CrossRefPubMed

12.

März W, Genser B, Drechsler C et al (2011) Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol 6:1316–1325CrossRefPubMedPubMedCentral

13.

Charytan DM, Sabatine MS, Pedersen TR et al (2019) Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol 73(23):2961–2970CrossRefPubMed

14.

Toth PP, Dwyer JP, Cannon CP et al (2018) Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 93(6):1397–1408CrossRefPubMed

15.

Nissen SE, Lincoff AM, Brennan D et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med 388(15):1353–1364CrossRefPubMed

16.

Saritas T, Floege J (2023) Retarding progression of chronic kidney disease. Inn Med 64(3):240–246

17.

Cheung AK, Chang TI, Cushman WC et al (2021) Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99(3):559–569CrossRefPubMed

18.

Wright JT Jr, Williamson JD, Whelton PK et al (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373(22):2103–2116CrossRefPubMed

19.

Dasgupta I, Zoccali C (2022) Is the KDIGO systolic blood pressure target <120 mm Hg for chronic kidney disease appropriate in routine clinical practice? Hypertension 79(1):4–11CrossRefPubMed

20.

Mebazaa A, Davison B, Chioncel O et al (2022) Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 400(10367):1938–1952CrossRefPubMed

21.

McDonagh TA, Metra M, Adamo M et al (2022) 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 24(1):4–131CrossRefPubMed

22.

Mullens W, Martens P, Testani JM et al (2022) Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 24(4):603–619CrossRefPubMed

23.

Mullens W, Damman K, Testani JM et al (2020) Evaluation of kidney function throughout the heart failure trajectory—A position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22(4):584–603CrossRefPubMed

24.

Kraus BJ, Weir MR, Bakris GL et al (2021) Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter‑2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. Kidney Int 99(3):750–762CrossRefPubMed

25.

Adamson C, Docherty KF, Heerspink HJL et al (2022) Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation 146(6):438–449CrossRefPubMedPubMedCentral

26.

Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383(15):1436–1446CrossRefPubMed

27.

Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42(5):373–498CrossRefPubMed

28.

Shafi T, Zhu X, Lirette ST, Rule AD et al (2022) Quantifying individual-level inaccuracy in glomerular filtration rate estimation: a cross-sectional study. Ann Intern Med 175(8):1073–1082CrossRefPubMed

29.

Chan KE, Lazarus JM, Thadhani R, Hakim RM (2009) Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20(10):2223–2233CrossRefPubMedPubMedCentral

30.

De Vriese AS, Heine G (2022) Anticoagulation management in haemodialysis patients with atrial fibrillation: evidence and opinion. Nephrol Dial Transplant 37(11):2072–2079CrossRefPubMed

31.

Pokorney SD, Chertow GM, Al-Khalidi HR et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146(23):1735–1745CrossRefPubMed

32.

De Vriese AS, Caluwé R, Van Der Meersch H et al (2021) Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 32(6):1474–1483CrossRefPubMedPubMedCentral

33.

Reinecke H, Engelbertz C, Bauersachs R et al (2023) A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation 147(4):296–309CrossRefPubMed

34.

Osmancik P, Herman D, Neuzil P et al (2022) 4‑year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol 79(1):1–14CrossRefPubMed

35.

Fink T, Paitazoglou C, Bergmann MW et al (2023) Left atrial appendage closure in end-stage renal disease and hemodialysis: data from a German multicenter registry. Catheter Cardiovasc Interv 101(3):610–619CrossRefPubMed

36.

Ha JT, Neuen BL, Cheng LP et al (2019) Benefits and harms of oral anticoagulant therapy in chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 171(3):181–189CrossRefPubMed

37.

Collet JP, Thiele H, Barbato E et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 42(14):1289–1367CrossRefPubMed

38.

Caruana J, Riva N, Vella K et al (2023) Navigating through the haemostatic paradox in kidney failure: a practical overview. Br J Haematol 202(2):230–247. https://doi.org/10.1111/bjh.18903CrossRefPubMed

39.

Yasuda S, Kaikita K, Akao M et al (2019) Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med 381(12):1103–1113CrossRefPubMed

40.

Steffel J, Collins R, Antz M et al (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612–1676CrossRefPubMed

Titel: Kardiovaskuläre Therapie bei chronischer Nierenerkrankung
verfasst von: Prof. Dr. Dr. med. Vincent Brandenburg
PD Dr. med. Turgay Saritas
Prof. Dr. Dr. med. Stephan H. Schirmer
PD Dr. med. Kyrill Rogacev
Prof. Dr. med. Gunnar Henrik Heine
Publikationsdatum: 11.09.2023
Verlag: Springer Medizin
Schlagwörter: Niere und Herz
Chronische Nierenerkrankung
Hypertonie
Hypercholesterinämie
Vorhofflimmern
Herzinsuffizienz
Embolieprophylaxe und Antikoagulation
Erschienen in: Herz / Ausgabe 5/2023
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-023-05205-2

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2023

Comparison of outcomes between single long stent and overlapping stents: a meta-analysis of the literature

Bildgebende Diagnostik der kardialen Sarkoidose

Computed tomography to guide transcatheter aortic valve implantation

Echokardiographie mit hohen Bildraten in der klinischen Praxis

Analysis of risk factors for systemic inflammatory response syndrome in patients after transcatheter aortic valve replacement

Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions